NKX-019 is under clinical development by Nkarta and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NKX-019’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NKX-019 overview
NKX-019 is under development for the treatment of B-cell malignancies including B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), diffuse large B-cell lymphoma, acute lymphoblastic leukemia and lupus nephritis. The therapeutic candidate (CAR-NK) constitutes of genetically manipulated allogeneic NK cells which express a chimeric antigen receptor targeting tumor cells expressing B lymphocyte antigen CD19, transduced by gamma-retrovirus. It is administered through intravenous route.
Nkarta overview
Nkarta a biopharmaceutical company that discovers, develops and commercialization allogeneic, off-the-shelf engineered natural killer (NK), cell therapies to treat cancer. The company product pipeline includes NKX101, NKX019 (CD19), CD70 and NK+T. Nkarta lead products candidate NKX101 is designed to enhance the power of innate NK biology to detect and kill cancerous cells and NKX019 to treat a variety of B-cell malignancies by targeting the clinically and commercially validated CD19 antigen that is found in different B-cell malignancies. The company also carries out research and development and clinical trials. Nkarta is headquartered in South San Francisco, California, the US.
For a complete picture of NKX-019’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
